NextCure Company Insiders
| NXTC Stock | USD 14.19 0.21 1.50% |
NextCure employs about 43 people. The company is managed by 12 executives with a total tenure of roughly 101 years, averaging almost 8.0 years of service per executive, having 3.58 employees per reported executive. Evaluation of NextCure's management performance can provide insight into the firm performance.
NextCure Management Team Effectiveness
The company has return on total asset (ROA) of (0.5801) % which means that it has lost $0.5801 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1691) %, meaning that it created substantial loss on money invested by shareholders. NextCure's management efficiency ratios could be used to measure how well NextCure manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of NextCure is $49.74 Million. NextCure holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as NextCure in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NextCure, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
NextCure Workforce Comparison
NextCure is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 419. NextCure retains roughly 43.0 in number of employees claiming about 10% of equities under Health Care industry.
NextCure Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NextCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on NextCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NextCure insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Richman Michael over three months ago Acquisition by Richman Michael of 305500 shares of NextCure at 0.8048 subject to Rule 16b-3 | ||
Jones Elaine V over six months ago Acquisition by Jones Elaine V of 14250 shares of NextCure at 8.21 subject to Rule 16b-3 | ||
Feigal Ellen over six months ago Acquisition by Feigal Ellen of 18700 shares of NextCure at 0.47 subject to Rule 16b-3 | ||
Myint Han over six months ago Acquisition by Myint Han of 103600 shares of NextCure at 5.57 subject to Rule 16b-3 | ||
Jones Elaine V over six months ago Acquisition by Jones Elaine V of 18700 shares of NextCure at 1.5 subject to Rule 16b-3 | ||
Sourav Kundu over six months ago Acquisition by Sourav Kundu of 75000 shares of NextCure at 1.55 subject to Rule 16b-3 | ||
Morrison Briggs over six months ago Acquisition by Morrison Briggs of 14250 shares of NextCure at 24.13 subject to Rule 16b-3 | ||
Timothy Mayer over six months ago Acquisition by Timothy Mayer of 93900 shares of NextCure at 2.23 subject to Rule 16b-3 |
NextCure Notable Stakeholders
A NextCure stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NextCure often face trade-offs trying to please all of them. NextCure's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NextCure's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| CPA CPA | Chief Officer | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Sebastien Maloveste | Senior Development | Profile | |
| Sourav Kundu | Senior Manufacturing | Profile | |
| Kevin Shaw | General Counsel | Profile | |
| Michael MSBA | CEO, CoFounder | Profile | |
| Lieping MD | CoFounder Board | Profile | |
| Timothy Mayer | Chief Officer | Profile | |
| MD FACP | Chief Officer | Profile | |
| Udayan MD | Senior Development | Profile | |
| Solomon Langermann | Chief Officer | Profile | |
| Stacy Rollinger | Vice Resources | Profile |
About NextCure Management Performance
The success or failure of an entity such as NextCure often depends on how effective the management is. NextCure management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NextCure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NextCure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Nextcure operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.
Please note, the presentation of NextCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NextCure's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NextCure's management manipulating its earnings.
NextCure Workforce Analysis
Traditionally, organizations such as NextCure use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NextCure within its industry.NextCure Manpower Efficiency
Return on NextCure Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 4.6M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 5.2M |
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |